{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:51Z","timestamp":1790812131287,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacl.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:00:53Z","timestamp":1755745253000},"page":"1550-1563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence, incidence, and definition of severe hypertriglyceridemia: A comprehensive review and weighted summary"],"prefix":"10.1016","volume":"19","author":[{"given":"Alexis","family":"Baass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-1275","authenticated-orcid":false,"given":"Martine","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-6768","authenticated-orcid":false,"given":"Otto","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-6541","authenticated-orcid":false,"given":"Kimberly","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica R.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacl.2025.08.012_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome-causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jacl.2025.08.012_bib0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/164_2021_520","article-title":"Metabolism of triglyceride-rich lipoproteins","volume":"270","author":"Boren","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"47","key":"10.1016\/j.jacl.2025.08.012_bib0003","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.08.012_bib0004","doi-asserted-by":"crossref","first-page":"a993","DOI":"10.1136\/bmj.a993","article-title":"Hypercholesterolaemia and its management","volume":"337","author":"Bhatnagar","year":"2008","journal-title":"BMJ."},{"issue":"4","key":"10.1016\/j.jacl.2025.08.012_bib0005","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacl.2017.05.014","article-title":"Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg\/dL)","volume":"11","author":"Kelly","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.08.012_bib0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fendo.2020.00616","article-title":"Hypertriglyceridemia-causes, significance, and approaches to therapy","volume":"11","author":"Santos-Baez","year":"2020","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.jacl.2025.08.012_bib0007","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.012_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacl.2025.08.012_bib0009","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.08.012_bib0011","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from: www.cochrane.org\/handbook. Accessed October 6, 2025."},{"key":"10.1016\/j.jacl.2025.08.012_bib0012","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 5: systematic reviews of prevalence and incidence","author":"Munn","year":"2020"},{"key":"10.1016\/j.jacl.2025.08.012_bib0013","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.012_bib0015","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","article-title":"Hypertriglyceridemia and its pharmacologic treatment among US adults","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacl.2018.03.021","article-title":"Prevalence of familial chylomicronemia syndrome (FCS): are we underestimating?","volume":"12","author":"Khavandi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0017","first-page":"275","article-title":"Comparison of LDL-C values measured with the automated method and the ultracentrifugation method in severe hypertriglyceridemia, and prevalence and life-style of patients with hypertriglyceridemia. [Japanese]","volume":"47","author":"Okubo","year":"1999","journal-title":"Jpn J Clin Pathol"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.012_bib0018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-021-01517-6","article-title":"Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study","volume":"20","author":"Berberich","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"11","key":"10.1016\/j.jacl.2025.08.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019343","article-title":"Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population-based study","volume":"10","author":"Saadatagah","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pan.2021.02.005","article-title":"Hypertriglyceridemia is often under recognized as an aetiologic risk factor for acute pancreatitis: A population-based cohort study","volume":"21","author":"Olesen","year":"2021","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2025.08.012_bib0022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijcard.2017.05.059","volume":"243","author":"Ponte-Negretti","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2025.08.012_bib0023","first-page":"18","article-title":"First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults","volume":"29","author":"Bagheri Kholenjani","year":"2024","journal-title":"J Res Med Sci"},{"issue":"Suppl 3","key":"10.1016\/j.jacl.2025.08.012_bib0024","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ihj.2014.12.001","article-title":"Consensus statement on management of dyslipidemia in Indian subjects","volume":"66","author":"Chandra","year":"2014","journal-title":"Indian Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0025","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016-part 1","volume":"2","author":"Iyengar","year":"2016","journal-title":"J Pract Cardiovasc Sci"},{"key":"10.1016\/j.jacl.2025.08.012_bib0026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.jacl.2025.08.012_bib0027","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"Suppl 5","key":"10.1016\/j.jacl.2025.08.012_bib0028","first-page":"v1","article-title":"Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice","volume":"91","year":"2005","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0029","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2337\/ds18-0009","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology management of dyslipidemia and prevention of cardiovascular disease clinical practice guidelines","volume":"31","author":"Jellinger","year":"2018","journal-title":"Diabetes Spectr"},{"issue":"9","key":"10.1016\/j.jacl.2025.08.012_bib0030","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2025.08.012_bib0031","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacl.2025.08.012_bib0032","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jacl.2025.08.012_bib0033","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0034","first-page":"1","article-title":"Triglyceride, high density lipoprotein, and coronary heart disease","volume":"10","year":"1992","journal-title":"Consens Statement"},{"issue":"8","key":"10.1016\/j.jacl.2025.08.012_bib0035","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-2275(20)31581-9","article-title":"High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey","volume":"42","author":"Aguilar-Salinas","year":"2001","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.012_bib0036","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"issue":"1-3","key":"10.1016\/j.jacl.2025.08.012_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12020-008-9100-z","article-title":"Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study","volume":"34","author":"Erem","year":"2008","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.012_bib0038","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12944-016-0328-y","article-title":"Dyslipidemia in rural areas of North China: prevalence, characteristics, and predictive value","volume":"15","author":"Gao","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"12","key":"10.1016\/j.jacl.2025.08.012_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144104","article-title":"The high prevalence of low HDL-cholesterol levels and dyslipidemia in rural populations in northwestern China","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.012_bib0040","first-page":"179","article-title":"Lipoprotein lipids and the prevalence of hyperlipidaemia in rural India","volume":"1","author":"Gupta","year":"1994","journal-title":"J Cardiovasc Risk"},{"issue":"4","key":"10.1016\/j.jacl.2025.08.012_bib0041","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pan.2012.05.002","article-title":"A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose","volume":"12","author":"Lindkvist","year":"2012","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.jacl.2025.08.012_bib0042","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/joim.12713","article-title":"Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men","volume":"283","author":"Pedersen","year":"2018","journal-title":"J Intern Med"},{"issue":"16_Supplement","key":"10.1016\/j.jacl.2025.08.012_bib0043","doi-asserted-by":"crossref","first-page":"C124","DOI":"10.1016\/j.jacc.2015.06.480","article-title":"High prevalence of dyslipidemia and associated risk factors among rural Chinese adults","volume":"66","author":"Sun","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.012_bib0044","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","article-title":"Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.012_bib0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacl.2023.09.002","article-title":"Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain","volume":"17","author":"Ortega","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.012_bib0046","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-022-01525-5","article-title":"Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study","volume":"21","author":"Patel","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0047","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurjpc\/zwad330","article-title":"Impact of hypertriglyceridaemia on cardiovascular mortality according to low-density lipoprotein cholesterol in a 15.6-million population","volume":"31","author":"Park","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0048","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacl.2025.02.008","article-title":"Epidemiology and longitudinal course of chylomicronemia: insights from NHANES and a large health care system","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0049","first-page":"284","article-title":"Identifying suspected familial chylomicronemia syndrome","volume":"31","author":"Rengarajan","year":"2018","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"11","key":"10.1016\/j.jacl.2025.08.012_bib0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.08.012_bib0051","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","article-title":"Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital","volume":"52","author":"Cartier","year":"2018","journal-title":"Clin Biochem"},{"issue":"23","key":"10.1016\/j.jacl.2025.08.012_bib0052","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1161\/01.CIR.0000148820.55611.6B","article-title":"Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles","volume":"110","author":"Ferreira","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2025.08.012_bib0053","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-9149(96)00760-6","article-title":"Effect of a single high-fat meal on endothelial function in healthy subjects","volume":"79","author":"Vogel","year":"1997","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2025.08.012_bib0054","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1001\/jama.1997.03550200058032","article-title":"Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal","volume":"278","author":"Plotnick","year":"1997","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.jacl.2025.08.012_bib0055","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/jn\/129.12.2184","article-title":"Postprandial triacylglycerols from dietary virgin olive oil are selectively cleared in humans","volume":"129","author":"Abia","year":"1999","journal-title":"J Nutr"},{"issue":"4","key":"10.1016\/j.jacl.2025.08.012_bib0056","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacl.2025.03.012","article-title":"Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:38:03Z","timestamp":1780472283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1933287425003769"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence, incidence, and definition of severe hypertriglyceridemia: A comprehensive review and weighted summary","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}